| Value—x (%) |
---|---|
HNC (n = 422) | |
Age (y) | |
 Mean | 50 |
 Range | 26–73 |
Gender (n) | |
 Male | 381 (90.3 %) |
 Female | 41 (9.7 %) |
Tumor site | |
 Larynx | 48 (11.4 %) |
 Hypopharynx | 68 (16.1 %) |
 Oropharynx | 54 (12.8 %) |
 Oral cavity | 102 (24.2 %) |
 Nasopharyngeal carcinoma | 150 (35.5 %) |
AJCC stage | |
 I | 0 |
 II | 34 (8.1 %) |
 III | 95 (22.5 %) |
 IV | 293 (69.4 %) |
Cochlea mean dose | |
 1–10 | 43 (10.2 %) |
 10–20 | 118 (28 %) |
 20–30 | 139 (32.9 %) |
 30–40 | 101 (23.9 %) |
 40–50 | 15 (3.6 %) |
 50–60 | 6 (1.4 %) |
Tinnitus (grade 2+) | |
 Yes | 49 (11.6 %) |
 No | 373 (88.4 %) |
Cochlea mean dose Gy (range) | 23.72 (1.73–58.83) |
 Without grade 2 + Tinnitus | 22.44 (1.73–50.26) |
 With grade 2 + Tinnitus | 33.46 (8.72–58.83) |
Chemotherapy | Â |
 Yes | 150 (35.5 %) |
 No | 272 (64.5 %) |